Tenofovir alafenamide is approved for HIV-1 and chronic hepatitis B treatment. It is used in combination therapy and offers strong viral suppression with lower kidney and bone toxicity compared to TDF.

Tenofovir alafenamide (TAF) is a prodrug that converts into active tenofovir diphosphate inside cells, where it blocks reverse transcriptase and stops viral DNA replication in HIV-1 and hepatitis B. It provides strong intracellular antiviral activity at lower doses, resulting in fewer systemic side effects.

Tenofovir alafenamide is taken orally once daily, either alone (for hepatitis B) or in combination tablets (for HIV-1). Dosing depends on age, weight, and kidney function. It should be taken consistently each day to maintain effective drug levels.

Tenofovir alafenamide is generally well tolerated, with common side effects such as headache, nausea, fatigue, and diarrhea. It has a lower risk of kidney and bone toxicity than TDF, but rare serious effects like liver problems, lactic acidosis, or hepatitis B flare may occur. Regular kidney and liver monitoring is advised.

Tenofovir alafenamide is contraindicated in individuals with known hypersensitivity to the drug. It should not be used alone for HIV due to the risk of resistance. Caution is needed in patients with severe kidney problems and in those with hepatitis B or C, as stopping TAF may worsen hepatitis. Use during pregnancy or breastfeeding should be based on a risk-benefit assessment. Regular monitoring of kidney and liver function is advised during treatment.

Tenofovir alafenamide is a well-tolerated antiviral used for HIV-1 and chronic hepatitis B, offering strong viral suppression with fewer kidney and bone risks than earlier formulations. Its once-daily dosing and improved tissue targeting make it suitable for long-term use, though monitoring and good adherence remain important.

Tenofovir alafenamide (TAF) is a newer prodrug of tenofovir that delivers the active drug more efficiently to cells, allowing for lower dosing and reduced systemic exposure. This results in fewer kidney and bone side effects compared to tenofovir disoproxil fumarate (TDF), while maintaining similar or improved antiviral efficacy.

TAF is safer for patients with mild to moderate renal impairment due to its lower plasma tenofovir levels. However, it is not recommended for patients with severe renal impairment unless they are on dialysis. Kidney function should be monitored regularly.

No, TAF should not be used alone to treat HIV. It must be combined with other antiretroviral agents to prevent resistance and achieve full viral suppression.

Stopping TAF in patients with chronic hepatitis B can lead to severe liver flare-ups or exacerbation. Liver function should be closely monitored after discontinuation, and patients should be advised not to stop therapy without medical guidance.

Limited human data suggest TAF may be safe during pregnancy and breastfeeding, but it should only be used if the benefits outweigh the risks. Physicians should assess each case individually and consider safer alternatives if needed.

Yes, TAF is approved for use in adolescents and children in certain formulations, depending on age and weight. Dosage adjustments and safety data vary by age group, so pediatric use should follow specific clinical guidelines.

Yes, TAF may interact with drugs that affect P-glycoprotein (P-gp) transporters or other antiretrovirals. Co-administration with strong P-gp inducers (e.g., rifampin, St. John's Wort) can reduce its effectiveness. Always review drug interactions before starting treatment.